Literature DB >> 17613540

Regulatory region single nucleotide polymorphisms of the apolipoprotein E gene and the rate of cognitive decline in Alzheimer's disease.

Olivia Belbin1, Janette L Dunn, Yan Ling, Linda Morgan, Sally Chappell, Helen Beaumont, Donald Warden, David A Smith, Noor Kalsheker, Kevin Morgan.   

Abstract

The aim of this study was to investigate whether single nucleotide polymorphisms (SNPs) in the regulatory regions of the apolipoprotein E (APOE) gene modify the well-established epsilon4-associated risk for Alzheimer's disease (AD). Sequencing of the APOE gene regulatory regions revealed four previously reported promoter SNPs and one novel SNP in the previously described macrophage enhancer (ME.1). In addition, we also studied the two classic allelic missense SNPs that define epsilon2/epsilon3/epsilon4 status in a case-control association study. Analysis of pair-wise linkage disequilibrium (LD) of the five regulatory region SNPs with classic APOE SNPs revealed a previously unreported 7 kb LD block covering the entire APOE gene, part of the promoter and 3' enhancer region. We report here that in a case-control association study (N=719) of the seven SNPs, the genotype at codon 112 captures all the information required to assess disease risk. To explore correlations with quantitative traits, 169 patients were studied in whom rates of cognitive decline were available. In addition to the epsilon4 allele, two regulatory region SNPs were associated with the rate of cognitive decline in AD patients. This study highlights the effect of APOE gene variation on risk of AD and rate of cognitive decline and demonstrates that a single SNP, which confers epsilon4 status, captures all of the risk of developing AD but two SNPs in the regulatory region may affect the rate of cognitive decline in AD patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17613540     DOI: 10.1093/hmg/ddm171

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  19 in total

Review 1.  Apolipoprotein E as a Therapeutic Target in Alzheimer's Disease: A Review of Basic Research and Clinical Evidence.

Authors:  Yu Yamazaki; Meghan M Painter; Guojun Bu; Takahisa Kanekiyo
Journal:  CNS Drugs       Date:  2016-09       Impact factor: 5.749

Review 2.  Overview of the development of personalized genomic medicine and surgery.

Authors:  F Charles Brunicardi; Richard A Gibbs; David A Wheeler; John Nemunaitis; William Fisher; John Goss; Changyi Chen
Journal:  World J Surg       Date:  2011-08       Impact factor: 3.352

3.  Alzheimer's disease risk variants show association with cerebrospinal fluid amyloid beta.

Authors:  John S K Kauwe; Jun Wang; Kevin Mayo; John C Morris; Anne M Fagan; David M Holtzman; Alison M Goate
Journal:  Neurogenetics       Date:  2008-09-24       Impact factor: 2.660

Review 4.  Molecular basis of etiological implications in Alzheimer's disease: focus on neuroinflammation.

Authors:  Rituraj Niranjan
Journal:  Mol Neurobiol       Date:  2013-02-19       Impact factor: 5.590

5.  Genetic associations with reflexive visual attention in infancy and childhood.

Authors:  Rebecca A Lundwall; James L Dannemiller; H Hill Goldsmith
Journal:  Dev Sci       Date:  2015-11-27

6.  MEIS1 intronic risk haplotype associated with restless legs syndrome affects its mRNA and protein expression levels.

Authors:  Lan Xiong; Hélène Catoire; Patrick Dion; Claudia Gaspar; Ronald G Lafrenière; Simon L Girard; Anastasia Levchenko; Jean-Baptiste Rivière; Laura Fiori; Judith St-Onge; Isabelle Bachand; Pascale Thibodeau; Richard Allen; Christopher Earley; Gustavo Turecki; Jacques Montplaisir; Guy A Rouleau
Journal:  Hum Mol Genet       Date:  2009-01-06       Impact factor: 6.150

7.  Functional characterization of three single-nucleotide polymorphisms present in the human APOE promoter sequence: Differential effects in neuronal cells and on DNA-protein interactions.

Authors:  Bryan Maloney; Yuan-Wen Ge; Ronald C Petersen; John Hardy; Jack T Rogers; Jordi Pérez-Tur; Debomoy K Lahiri
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2010-01-05       Impact factor: 3.568

8.  APOE polymorphisms and cognitive functions in patients with brain tumors.

Authors:  Denise D Correa; Jaya Satagopan; Raymond E Baser; Kenneth Cheung; Elizabeth Richards; Michael Lin; Sasan Karimi; John Lyo; Lisa M DeAngelis; Irene Orlow
Journal:  Neurology       Date:  2014-06-18       Impact factor: 9.910

9.  Characterizing Clinical and Neuropathological Traits of APOE Haplotypes in African Americans and Europeans.

Authors:  Aziz M Mezlini; Colin Magdamo; Emily Merrill; Lori B Chibnik; Deborah L Blacker; Bradley T Hyman; Sudeshna Das
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

10.  Associations between APOE genotypes and disease susceptibility, joint damage and lipid levels in patients with rheumatoid arthritis.

Authors:  Marthe T Maehlen; Sella A Provan; Diederik P C de Rooy; Annette H M van der Helm-van Mil; Annemarie Krabben; Tore Saxne; Elisabet Lindqvist; Anne Grete Semb; Till Uhlig; Désirée van der Heijde; Inger Lise Mero; Inge C Olsen; Tore K Kvien; Benedicte A Lie
Journal:  PLoS One       Date:  2013-04-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.